Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
5
|
pubmed:dateCreated |
1993-5-18
|
pubmed:abstractText |
Dihydropyrimidine dehydrogenase (DPD) is the major catabolic enzyme of pyrimidines and fluoropyrimidines. The clinical course of 2 patients with suspected DPD deficiency is described. Both patients had significantly delayed clearance of fluorouracil (5-FU), elevated plasma uracil concentrations, and subsequent lethal toxicity. The prevalence of DPD deficiency in the general population is unknown, but given the large number of cancer patients treated with 5-FU, it may be of great clinical significance. Lymphocytes have been previously shown to be a useful marker of systemic DPD activity. Because DPD activity has not been previously reported in a large population of cancer patients using 5-FU as the substrate, we determined DPD activity in lymphocytes from 66 patients with cancer. DPD activity was determined by a sensitive high performance liquid chromatography method. The mean DPD activity (S.D.) in 66 patients with head and neck cancer was 0.189 (0.071) nomol/min/mg protein with wide interpatient variability (range 0.058-0.357). DPD activity was not correlated to age (r = -0.164, P = 0.188). The mean DPD activity in men [0.192 (0.074)] was not significantly different from that in women [0.172 (0.057); t-test P = 0.418]. Likewise, there was no statistical difference in DPD activity in patients who had not received prior chemotherapy [0.195 (0.066)] to patients receiving one or more cycles of chemotherapy [0.186 (0.074); t-test P = 0.638].
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:issn |
0959-8049
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
29A
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
740-4
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:8471333-Adult,
pubmed-meshheading:8471333-Aged,
pubmed-meshheading:8471333-Aged, 80 and over,
pubmed-meshheading:8471333-Dihydrouracil Dehydrogenase (NADP),
pubmed-meshheading:8471333-Female,
pubmed-meshheading:8471333-Fluorouracil,
pubmed-meshheading:8471333-Head and Neck Neoplasms,
pubmed-meshheading:8471333-Humans,
pubmed-meshheading:8471333-Lymphocytes,
pubmed-meshheading:8471333-Male,
pubmed-meshheading:8471333-Middle Aged,
pubmed-meshheading:8471333-Oxidoreductases,
pubmed-meshheading:8471333-Pancreatic Neoplasms,
pubmed-meshheading:8471333-Uracil
|
pubmed:year |
1993
|
pubmed:articleTitle |
Dihydropyrimidine dehydrogenase activity in cancer patients.
|
pubmed:affiliation |
Laboratoire d'Oncopharmacologie, Centre Antoine Lacassagne, Nice, France.
|
pubmed:publicationType |
Journal Article,
Case Reports,
Research Support, Non-U.S. Gov't
|